Technology evaluation: Alicaforsen, Isis

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 3, 2005, Pages 273-281

  Gewirtz, Andrew T ^a   Sitaraman, Shanthi V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; ISIS 1570; ISIS 15839; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN INHIBITOR; RIBONUCLEASE; STEROID;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; ASTHENIA; ASTHMA; CHILL; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SYNTHESIS; ENTERITIS; FEVER; FLU LIKE SYNDROME; GRAFT REJECTION; HEADACHE; HUMAN; INJECTION SITE REACTION; NAUSEA; NONHUMAN; PAIN; PATENT; REVIEW; ULCERATIVE COLITIS; VOMITING;

ANIMALS; CLINICAL TRIALS, PHASE II; COLITIS, ULCERATIVE; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES;

EID: 20344376162     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. 170847 Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. Bennett CF, Condon TP, Grimm S, Chan H, Chiang MY J IMMUNOL 1994 152 7 3530-3540
2. 174111 BI/Isis to collaborate in cell adhesion. SCRIP WORLD PHARMACEUTICAL NEWS 1995 2005 9
3. 175741 Annual Report. Isis Pharmaceuticals Inc ANNUAL REPORT 1994 December 31
4. 177110 Oligonucleotide conjugates aimed to improve the pharmacokinetic properties of antisense agents. Manoharan M, Tivel KL, Barber-Poec'h I, Andrade LK, Mohan V, Sasmor H, Bennett F, Condon TP, Cook PD ACS 1995 209 Abs MEDI 002
5. 204226 Pharmacokinetics of ISIS-2302, a phosphorothioate (P=S) oligonucleotide, in cynomolgus monkeys after intravenous infusion and bolus injection. Zuckerman JE, Leeds JM, Truong L, Henry SP, Kornbrust DJ PHARM RES 1995 12 9 Suppl Abs S344
6. 204228 Effects of ISIS-2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Henry SP, Larkin R, Novotny WF, Kombrust DJ PHARM RES 1994 11 10 Suppl Abs S353
7. 212289 Patent news update. SCRIP WORLD PHARMACEUTICAL NEWS 1996 2138 18
8. 218443 Phase 1 study of an ICAM-1 antisense oligonucleotide (ISIS 2302). Shanahan W, Gover J, Mant T, Amin D, Leeds J, Zuckerman J, Levin A CLIN PHARMACOL THER 1996 59 2 Abs 208
9. 220889 Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF J BIOL CHEM 1991 226 27 18162-18171
10. 227637 Boehringer Ingelheim and Isis reach first milestone for ISIS-2302. Boehringer Ingelheim Corp PRESS RELEASE 1996 December 03
11. 227638 Isis receives $10 million milestone payment from Boehringer Ingelheim for ISIS-2302. ISIS Pharmaceuticals Inc PRESS RELEASE 1996 December 03
12. 229221 Isis receives second payment from Boehringer Ingelheim on line of credit to support cell adhesion collaboration. ISIS Pharmaceuticals Inc PRESS RELEASE 1997 January 06
13. 234792 Isis receives thirteen patents covering antisense biology, chemistry and combinatorial chemistry novel biology targets include Ras, cell adhesion, CMV, HIV and flu. Isis Pharmaceuticals Inc PRESS RELEASE 1997 February 19
14. 239373 Single dose subcutaneous bioavailability of ISIS 2302, a phosphorothioate oligonucleotide, in cynomolgus monkeys. Leeds JM, Kiorpes A, Geary R, Henry SP, Goldensoph C, Levin AA PHARM RES 1996 13 9 Suppl Abs S395
15. 258276 Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Henry SP, Bolte H, Auletta C, Kornbrust DJ TOXICOLOGY 1997 120 2 145-155
16. 262274 Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras. Christofidou-Solomidou M, Albelda SM, Bennett FC, Murphy GF AM J PATHOL 1997 150 2 631-639
17. 268843 Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR J PHARMACOL EXP THER 1997 282 3 1173-1180
18. 269427 Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ ANTISENSE NUCLEIC ACID DRUG DEV 1997 7 5 473-481
19. 272307 Inhibition of coagulation by a phosphorothioate oligonucleotide. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ ANTISENSE NUCLEIC ACID DRUG DEV 1997 7 5 503-510
20. 272308 Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Butler M, Stecker K, Bennett CF LAB INVEST 1997 77 4 379-388
21. 276249 Efforts toward synthesis of oligonucleotides for commercialization. Andrade M, Scozzari AS, Cole DL, Ravikumar VT NUCLEOSIDES NUCLEOTIDES 1997 16 7-9 1617-1620
22. 276313 Pharmacokinetic properties of phosphorothioate oligonucleotides. Leeds JM, Geary RS, Henry SP, Glover J, Shanaha W, Fitchett J, Burckin T, Truong L, Levin AA NUCLEOSIDES NUCLEOTIDES 1997 16 7-9 1689-1693
23. 277320 Isis Pharmaceuticals - mid-year report 1997. Isis Pharmaceuticals Inc 2ND QUARTER REPORT 1997 June
24. 277371 An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI J PHARMACOL EXP THER 1997 280 2 988-1000
25. 289158 Isis Crohn's disease drug shows evidence of durable remission, steroid-sparing and fistula healing effects results of phase II trial show inhibition of ICAM-1 and other inflammatory markers, supporting antisense mechanism. Isis Pharmaceuticals Inc PRESS RELEASE 1998 June 10
26. 318398 TNF Second International Meeting (Part II): A validated target with multiple therapeutic potential. Clover SJ, Zeldis JB IDDB MEETING REPORT 1999 February 24-25
27. 320271 Antisense oligonucleotide therapeutics. Bennett CF EXPERT OPIN INVESTIG DRUGS 1999 8 3 237-253
28. 328947 A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Yacyshyn BR, Bowen Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan Jr WR GASTROENTEROLOGY 1998 114 6 1133-1142
29. 335002 Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Henry SP, Templin MV, Gillett N, Rojko J, Levin AA TOXICOL PATHOL 1999 27 1 95-100
30. 335176 Safety of retreatment with antisense to ICAM-1 (ISIS 2302) in patients with steroid-dependent Crohn's disease. Yacyshyn BR, Bowen-Yacyshyn MB, Tami J, Sahba B, Shanahan W GASTROENTEROLOGY 1998 114 4 Pt 2 Abs A1118
31. 338670 Isis reacquires full rights to ISIS-2302; Isis plans NDA filing in early 2000 pending review of data. ISIS Pharmaceuticals Inc PRESS RELEASE 1999 September 02
32. 338672 Isis in late stage negotiations to commercialize ISIS-2302. ISIS Pharmaceuticals Inc PRESS RELEASE 1999 September 02
33. 343460 Annual Report 1998 Isis Pharmaceuticals Inc ANNUAL REPORT 1998 December 31
34. 347579 Isis presents data from phase II trial of ISIS 2302 in rheumatoid arthritis. Isis Pharmaceuticals Inc PRESS RELEASE 1999 November 15
35. 349641 Isis begins phase IIa study of ISIS 2302 for ulcerative colitis. Isis Pharmaceuticals Inc PRESS RELEASE 1999 December 07
36. 349990 Isis begins phase IIa studies of ISIS 2302 for psoriasis. Isis Pharmaceuticals Inc PRESS RELEASE 1999 December 09
37. 350793 Isis announces disappointing results from ISIS 2302 clinical trial in Crohn's disease. Isis Pharmaceuticals Inc PRESS RELEASE 1999 December 15
38. 366813 Anti-sense ICAM-1 (ISIS-2302) for subcutaneous treatment of chronic active Crohn's disease (CACD): Lack of efficacy in a prospective, double-blind, multicenter randomized trial. Schreiber S, Malchow H, Kruis W, Lochs H, Hahn E, Steinmann G GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 2971
39. 366820 Double-blinded, randomized, placebo-controlled trial of the remission of two schedules of ISIS-2302 (ICAM-1 antisense) in active, steroid-dependent Crohn's disease. Yacyshyn BR, Chey W, Goff J, Salzberg B, Buchman A, Baerg R, Anderson F, Koval G, Barish C, Safdi M, Rutgeerts P, Shanahan W GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 2977
40. 384820 Isis Pharmaceuticals to reinitiate development of ISIS 2302 in Crohn's disease final analysis of clinical trial shows response to drug in patients with higher levels of exposure. Isis Pharmaceuticals Inc PRESS RELEASE 2000 October 04
41. 393793 Antisense drugs topically delivered to skin inhibit gene associated with psoriasis; study published in the Journal of Investigative Dermatology, preclinical research serves as cornerstone of Isis Pharmaceuticals dermatology program. Isis Pharmaceuticals Inc PRESS RELEASE 2000 December 14
42. 402900 Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Leeds JM, Henry SP, Geary R, Burckin T, Levin AA ANTISENSE NUCLEIC ACID DRUG DEV 2000 10 6 435-441
43. 406261 Population pharmacokinetics of ISIS 2302. Gibiansky L, Gibiansky E, Yu RZ, Geary RS AM SOC CLIN PHARMACOL THER 2001 42 Abs PI-105
44. 413512 Phase II clinical trial of ISIS 2302 suggests topical antisense drug penetrates and reduces thickness in patients' psoriatic plaques high drug levels in plaques support potential of dermatological antisense drug discovery program. Isis Pharmaceuticals Inc PRESS RELEASE 2001 June 25
45. 425063 Annual Report 2000 - Isis Pharmaceuticals. Isis Pharmaceuticals Inc ANNUAL REPORT 2000 December 31
46. 425103 Phase II study of antisense drug ISIS 2302 demonstrates significant and long-lasting improvement of symptoms in patients with ulcerative colitis. Isis Pharmaceuticals Inc PRESS RELEASE 2001 October 10
47. 441190 Isis Pharmaceuticals reports phase II study results of topical alicaforsen, ISIS 2302, in psoriasis. Isis Pharmaceuticals Inc PRESS RELEASE 2002 February 25
48. 462303 Pilot study of topical ISIS 2302, an antisense oligodeoxynucleotide, in patients with plaque type psoriasis vulgarls. Leonardi C, Tami J, Sewell KL ANNU MEET AM ACAD DERMATOL 2002 February 22-27 Abs P28
49. 463930 Isis Pharmaceuticals Inc: Pipeline. Isis Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2002 July 22
50. 467402 Alicaforsen (ISIS 2302) Improves potential for responses and remissions in patients with Crohn's disease. Isis Pharmaceuticals Inc PRESS RELEASE 2002 October 21
51. 469960 American College of Gastroenterology - 67th Annual Scientific Meeting, Seattle, WA, USA. Susman E IDDB MEETING REPORT 2002 October 19-23
52. 471163 Isis Pharmaceuticals initiates phase II clinical trial of alicaforsen, ISIS 2302, in patients with ulcerative colitis. Isis Pharmaceuticals Inc PRESS RELEASE 2002 November 21
53. 479196 Antisense and siRNA Technologies - SMi Conference. Gotham S IDDB MEETING REPORT 2003 February 12-13
54. 485044 Isis Pharmaceuticals initiates additional phase II clinical trial of alicaforsen, ISIS 2302, in patients with ulcerative colitis. Isis Pharmaceuticals Inc PRESS RELEASE 2003 April 08
55. 490469 Alicaforsen (ISIS 2302) improves clinical symptoms of pouchitis patients. Isis Pharmaceuticals Inc PRESS RELEASE 2003 May 21
56. 490701 Antisense inhibitor of ICAM-1 given as enema improves symptomatic pouchitis. Miner PB, Bane BL, Sadiq SA, Bradley JD, Wedel M GASTROENTEROLOGY 2003 124 Suppl 1 Abs T1395
57. 510492 Isis Pharmaceuticals updates positive clinical data on multiple antisense drugs. Isis Pharmaceuticals Inc PRESS RELEASE 2003 October 27
58. 513308 Isis pipeline at-a-glance. Isis Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2003 July 18
59. 519367 Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: Comparison of proposed dosing regimens. Yu RZ, Su JQ, Grundy JS, Geary RS, Sewell K, Dorr A, Levin AR ANTISENSE NUCLEIC ACID DRUG DEV 2003 13 1 57-66
60. 519368 Dose ranging pharmacokinetic trial of high-dose alicaforsen (intracellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Yacyshyn BR, Barish C, Goff J, Dalke D, Gasperi M, Yu R, Tami J, Dorr FA, Sewell KL ALIMENT PHARMACOL THER 2002 16 10 1761-1770
61. 519369 Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR GUT 2002 51 130-36
62. 562821 Antisense phosphorothioate oligodeoxyribonucleotide targeted against ICAM-1: Synthetic and biological characterization of a process-related impurity formed during oligonucleotide synthesis. Ravikumar VT, Capaldi DC, Lima WF, Lesnik E, Turney B, Cole DL BIOORG MED CHEM 2003 11 21 4673-4679
63. 562900 Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM 1 Study Group GASTROENTEROLOGY 2001 120 6 1339-1346
64. 562902 An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Miner PJ, Wedel M, Bane B, Bradley J ALIMENT PHARMACOL THER 2004 19 3 281-286
65. 573948 Isis Pharmaceuticals announces results of alicaforsen phase 3 clinical trials in patients with Crohn's disease. Isis Pharmaceuticals Inc PRESS RELEASE 2004 December 02
66. 573949 Alicaforsen significantly improves symptoms and produces durable responses in patients with ulcerative colitis. Isis Pharmaceuticals Inc PRESS RELEASE 2004 December 02
67. 578943 Isis tightens belt for 2005. Isis Pharmaceuticals Inc PRESS RELEASE 2005 January 10
68. 600712 Isis Pharmaceuticals, Inc. (ISIS/NASDAQ). Monane M, Fulop G, Wilson C NEEDHAM AND COMPANY 2005 April 22